NATICK, Mass., Nov. 14 /PRNewswire-FirstCall/ -- Boston Scientific Corporation announced today the pricing of a public offering of $750 million aggregate principal amount of its senior notes under the Company’s existing shelf-registration statement. The public offering consists of $400 million of 5.50 percent notes due November 15, 2015 and $350 million of 6.25 percent notes due November 15, 2035. The Company expects to receive the offering proceeds upon closing on November 17, 2005, subject to standard closing conditions. Boston Scientific plans to use the net offering proceeds to repay commercial paper borrowings and for other general corporate purposes.
Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification under the securities laws of any such state or jurisdiction. The offering is being made by means of a prospectus and related preliminary prospectus supplement only, copies of which or information concerning this offering may be obtained by contacting the joint bookrunners: Deutsche Bank Securities, Attn: Debt Capital Markets, 60 Wall Street, New York, NY 10005, (212) 250-2500; JPMorgan, Attn: High Grade Syndicate Desk, 270 Park Ave., 8th Floor, New York, NY 10017, (212) 834-4533; or UBS Investment Bank, Attn: Michele Hagedus, 677 Washington Blvd., Stamford, CT 06901, (203) 719-1088.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.
This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward looking statements and may be adversely affected by, among other things, risks associated with capital markets, new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, integration of acquired companies, the Company’s overall business strategy, and other factors described in the Company’s filings with the Securities and Exchange Commission.
CONTACT: Milan Kofol Paul Donovan 508-650-8569 508-650-8541 Investor Relations Media Relations Boston Scientific Corporation Boston Scientific Corporation
Boston Scientific Corporation
CONTACT: Milan Kofol, Investor Relations, +1-508-650-8569, or PaulDonovan, Media Relations, +1-508-650-8541, both of Boston ScientificCorporation
Web site: http://www.bostonscientific.com//
